AzTrials
AzTrials

ArthritisPhase 3NCT00744471

Tanezumab in Osteoarthritis Of The Hip

A Phase 3 study testing tanezumab in people with Arthritis and Osteoarthritis, run by Pfizer at 99 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Arthritis, Osteoarthritis, Osteoarthritis, Hip
What is being tested?
tanezumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
627 participants
Where
99 sitesUnited States
Study dates
17 Nov 2008to 13 Aug 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Osteoarthritis of the hip according to ACR criteria with Kellgren-Lawrence x-ray grade of 2
  • Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for Hip injections, arthroplasty or replacement surgery
  • Pain level and function levels as required by the protocol at Screening and Baseline
  • Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study
  • Must agree to the contraceptive requirements of the protocol if applicable
  • Must agree to the treatment plan, scheduled visits, and procedures of the protocol

Who cannot join

  • Pregnancy
  • BMI greater than 39
  • Other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

Trial locations and contacts

99 sites in 1 country.

99 sites in 1 country

United States99 sites
  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico, 87102

  • New Mexico Clinical Research & Osteoporosis Center, Incorporated

    Albuquerque, New Mexico, 87106

  • Ann Arbor Clinical Research

    Ann Arbor, Michigan, 48103

  • Arthritis and Rheumatology of Georgia

    Atlanta, Georgia, 30342

  • Laureate Clinical Reseach Group

    Atlanta, Georgia, 30342

  • Maine Research Associates

    Auburn, Maine, 04210

  • Capital Medical Clinic

    Austin, Texas, 78705

  • Walter Chase MD

    Austin, Texas, 78705

  • EPIC Imaging West

    Beaverton, Oregon, 97008

  • Comprehensive Clinical Research

    Berlin, New Jersey, 08009

  • East Penn Rheumatology Associates, PC

    Bethlehem, Pennsylvania, 18015

  • Sonora Clinical Research

    Boise, Idaho, 83702

  • Arthritis and Osteoporosis Center of Brooklyn Heights

    Brooklyn, New York, 11201

  • Providence Clinical Research

    Burbank, California, 91505

  • Carolina Bone & Joint, P.A.

    Charlotte, North Carolina, 28210

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911

  • Consultants for Clinical Research/Ohio GI and Liver Institute

    Cincinnati, Ohio, 45219

  • Hilltop Physicians Inc, Hightop Medical Research Center

    Cincinnati, Ohio, 45224

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida, 33756

  • Tampa Bay Medical Research Inc

    Clearwater, Florida, 33761

  • Radiant Research

    Dallas, Texas, 75231

  • Clinical Research Center of Connecticut

    Danbury, Connecticut, 06810

  • Avail Clinical Research, LLC

    DeLand, Florida, 32720

  • Avail Clinical Research

    DeLand, Florida, 32720

  • Arthritis Associates of South Florida

    Delray Beach, Florida, 33484

  • Delray Research Associates

    Delray Beach, Florida, 33484

  • Brandywine Clinical Research

    Downingtown, Pennsylvania, 19335-2620

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • MAPS Applied Research Center

    Edina, Minnesota, 55435

  • Medical Advanced Pain Specialists

    Edina, Minnesota, 55435

  • Arthritis Medical Clinic of North County, Inc.

    Escondido, California, 92025

  • American Health Network of IN, LLC

    Fishers, Indiana, 46038

  • Early Family Practice Center

    Fort Valley, Georgia, 31030

  • The Arthritis and Osteoporosis Center of Maryland

    Frederick, Maryland, 21702

  • Northeast Georgia Diagnostic Clinic

    Gainesville, Georgia, 30501

  • Pharmquest

    Greensboro, North Carolina, 27408

  • St. Joseph's Mercy Clinic

    Hot Springs, Arkansas, 71913

  • Rheumatic Disease Clinical Research Center

    Houston, Texas, 77004

  • Pioneer Research Solutions

    Houston, Texas, 77008

  • Pioneet Research Solutions, Inc

    Houston, Texas, 77036

  • Talbert Medical Group

    Huntington Beach, California, 92646

  • Westside Center for Clinical Research

    Jacksonville, Florida, 32205

  • Appalachian Medical Research Inc.

    Johnson City, Tennessee, 37604-1417

  • Rheumatology, PC

    Kalamazoo, Michigan, 49009

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • Clinical Research Consortium

    Las Vegas, Nevada, 89119

  • Mirkil Medical

    Las Vegas, Nevada, 89119

  • Office of Dr. Danka Michaels, MD

    Las Vegas, Nevada, 89128

  • Adult Medicine Specialists

    Longwood, Florida, 32779

  • Genesis Research International

    Longwood, Florida, 32779

  • Mansfield Health Center

    Mansfield, Massachusetts, 02048

  • North Georgia Clinical Research

    Marietta, Georgia, 30060

  • International Research Associates, LLC

    Miami, Florida, 33183

  • Southwest Rheumatology and Research Group, LLC

    Middleburg Heights, Ohio, 44130

  • Horizon Research Group

    Mobile, Alabama, 36608

  • Arthritis and Diabetes Clinic

    Monroe, Louisiana, 71203

  • The Medical Research Network, LLC

    New York, New York, 10128

  • Javed Rheumatology Associates, Inc.

    Newark, Delaware, 19713

  • Health Research Institute

    Oklahoma City, Oklahoma, 73109

  • Quality Clinical Research, Inc.

    Omaha, Nebraska, 68114

  • Compass Research, LLC

    Orlando, Florida, 32806

  • The Arthritis Center

    Palm Harbor, Florida, 34684

  • Arizona Arthritis & Rheumatology Associates, PC

    Paradise Valley, Arizona, 85253

  • Pivotal Research Center

    Peoria, Arizona, 85381

  • Arizona Research Center, Inc.

    Phoenix, Arizona, 85023

  • Clinical Research Advantage, Inc. /Stonecreek Medical Associates, PC

    Phoenix, Arizona, 85028

  • Arizona Arthritis & Rheumatology Associates, PC

    Phoenix, Arizona, 85037

  • Advent Clinical Research Centers

    Pinellas Park, Florida, 33781

  • Prem C. Chatpar, MD, LLC

    Plainview, New York, 11803

  • Clinical Investigations of Texas, LLC

    Plano, Texas, 75075

  • Avivoclin Clinical Services

    Port Orange, Florida, 32127

  • Accord Clinical Research, LLC

    Port Orange, Florida, 32129

  • EPIC Imaging East

    Portland, Oregon, 97220

  • Covance CRU, Inc.

    Portland, Oregon, 97239

  • Health Concepts

    Rapid City, South Dakota, 57702

  • Office of Dr. Andrew Porges

    Roslyn, New York, 11576-1507

  • Optimum Clinical Research

    Salt Lake City, Utah, 84102

  • Radiant Research San Antonio NE

    San Antonio, Texas, 78217

  • Texas Arthritis Research Center, PA

    San Antonio, Texas, 78217

  • Diagnostics Research Group

    San Antonio, Texas, 78229

  • Trinity Clinical Trials

    Santa Ana, California, 92701

  • Sushma V. Gorrela, MD

    Spring, Texas, 77379

  • The Arthritis Center

    Springfield, Illinois, 62704

  • Mercy Health Research

    St Louis, Missouri, 63141

  • All Florida Orthopaedic Associates

    St. Petersburg, Florida, 33703

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905

  • Internal Medicine Northwest, Frank S Baker Center

    Tacoma, Washington, 98405-4260

  • Quality of Life Medical & Research Center, LLC

    Tucson, Arizona, 85712

  • Quality of Life Medical and Research Center

    Tucson, Arizona, 85712

  • Tucson Orthopaedic Institute

    Tucson, Arizona, 85712

  • Northwest Indiana Center for Clinical Research

    Valparaiso, Indiana, 46383

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Piedmont Medical Research Associates

    Winston-Salem, North Carolina, 27103

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189

  • North Georgia Internal medicine

    Woodstock, Georgia, 30189

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01610

  • Clinical Trials Northwest

    Yakima, Washington, 98902

  • Pharmacotherapy Research Associates,Inc

    Zanesville, Ohio, 43701

Other trials in United States

About this study

Official title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP.

The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients

Being tested
tanezumab, Placebo
Keywords
monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth OA
Medical subject headings
Arthritis, Osteoarthritis, Osteoarthritis, Hip

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tanezumabBiological

    Tanezumab 10 mg IV every 8 weeks

  • tanezumabBiological

    Tanezumab 5mg IV every 8 weeks

  • tanezumabBiological

    Tanezumab 2.5 mg IV every 8 weeks.

  • PlaceboBiological

    Placebo to match tanezumab IV every 8 weeks

Study groups in NCT00744471
Study groupRoleWhat they receive
Tanezumab 10 mgExperimentalTanezumab 10 mg IV every 8 weeks
Receives: Biological: tanezumab
Tanezumab 5 mgExperimentalTanezumab 5mg IV every 8 weeks
Receives: Biological: tanezumab
Tanezumab 2.5 mgExperimentalTanezumab 2.5 mg IV every 8 weeks.
Receives: Biological: tanezumab
PlaceboExperimentalPlacebo
Receives: Biological: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline (Day 1), Week 16

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 16

  3. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your hip joint affects you, how are you doing today?", participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities), where lower scores indicates better condition.

    Measured: Baseline, Week 16

Secondary outcomes (27)
  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Pain Subscale Score at Week 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 24

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Pain Subscale Score at Week 2, 4, 8, 12,16 and 24: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  3. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Subscale Score at Week 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 2, 4, 8, 12, 24

  4. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Subscale at Week 2, 4, 8, 12, 16 and 24: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions scored on a NRS of 0 to 10, where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 to 10, where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  5. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your hip joint affects you, how are you doing today?", participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities), where lower scores indicates better condition.

    Measured: Baseline, Week 2, 4, 8, 12, 24

  6. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 16 and 24: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your hip joint affects you, how are you doing today?", participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities), where lower scores indicates better condition.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  7. Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)

    A participant was considered as an OMERACT-OARSI responder if at least one of the following criteria were met: Improvement in WOMAC pain or physical function subscale from baseline to week of interest was greater than or equal to (>=) 50 percent (%)and absolute change of >=2 units from baseline at the week of interest, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at the week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis. Score range for PGA: 1 = very good to 5 = very poor, where higher scores=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0 [no pain] to 10 [worst possible pain], higher score=higher pain/difficulty).

    Measured: Week 2, 4, 8, 12, 16, 24

  8. Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)

    A participant was considered as an OMERACT-OARSI responder if at least one of the following criteria were met: Improvement in WOMAC pain or physical function subscale from baseline to week of interest was greater than or equal to (>=) 50 percent (%)and absolute change of >=2 units from baseline at the week of interest, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at the week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis. Score range for PGA: 1 = very good to 5 = very poor, where higher scores=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0 [no pain] to 10 [worst possible pain], higher score=higher pain/difficulty).

    Measured: Week 2, 4, 8, 12 ,16, 24

  9. Percentage of Participants With at Least 30 Percent (%), and 50 % Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants with >=30% or >=50% reduction in WOMAC pain subscale score from baseline to specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  10. Percentage of Participants With at Least 30 Percent (%), and 50% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Percentage of participants with >=30% or >=50% reduction in WOMAC pain subscale score from baseline to specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  11. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12 ,16 and 24: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?", participants responded by using a 5-point scale where 1 = very good and 5 = very poor where lower scores indicating better condition. Percentage of participants with an improvement of greater than or equal to 2 points from baseline at specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12 ,16, 24

  12. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?", participants responded by using a 5-point scale where 1 = very good and 5 = very poor where lower scores indicating better condition. Percentage of participants with an improvement of greater than or equal to 2 points from baseline at specified weeks were reported.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  13. Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 were reported.

    Measured: Baseline, Week 16

  14. Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a NRS of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 were reported.

    Measured: Baseline, Week 16

  15. Change From Baseline in Average Daily Pain Score in the Hip Joint at Week 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    Participants assessed daily average hip joint pain during the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Post baseline weekly scores were calculated as the mean of the scores over the last 7 days prior to each assessment time point.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  16. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Week 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in hip joint during past 48 hours. It is calculated as mean of the scores from 2 individual questions each scored on numerical rating scale of 0 (minimum stiffness) to 10 (maximum stiffness), giving an overall possible mean score range of 0 (minimum stiffness) to 10 (maximum stiffness). Higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of hip joint.

    Measured: Baseline, Week 2, 4, 8, 12 ,16, 24

  17. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) Average Score at Week 2, 4, 8, 12,16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of hip joint. Each item is scored on a 0 (no pain) to 10 (worst possible pain) NRS scale, where higher scores indicate higher pain/stiffness or worse function. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 (no pain) to 10 (worst possible pain), where higher score indicates worse response.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  18. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) Pain Subscale Item (Pain When Walking on Flat Surface) Score at Week 2, 4, 8, 12, 16 and 24 : Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. Participants answered "How much pain have you had when walking on a flat surface?". Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 =extreme pain. Higher scores indicated more pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  19. Change From Baseline of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale (Pain When Going up or Down Stairs) Score at Week 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis. Participants answered "How much pain have you had when going up or down the stairs?". Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = worst possible pain, where higher scores indicating higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  20. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 24: Baseline Observation Carried Forward (BOCF)

    The SF-36 health survey was a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher score indicates highest level of functioning.

    Measured: Baseline, Week 12, 24

  21. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12 and 24: Baseline Observation Carried Forward (BOCF)

    The SF-36 health survey was a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher score indicates highest level of functioning. These 8 domains were also summarized as summary scores: mental component aggregate (MCA) and physical component aggregate (PCA). Total score range for the each summary scores =0 to 100, where higher scores represented higher level of functioning. Higher summary scores indicated a better health related quality of life.

    Measured: Baseline, Week 12, 24

  22. Time to Discontinuation Due to Lack of Efficacy

    Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.

    Measured: Baseline up to Week 16

  23. Percentage of Participants Who Used Rescue Medication

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. Percentage of participants with any use of rescue medication during the particular study week were summarized.

    Measured: Week 2, 4, 8, 12 ,16, 24

  24. Duration of Rescue Medication Use

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. Number of days participant used any of the rescue medication, during the specified week were summarized.

    Measured: Week 2, 4, 8, 12, 16, 24

  25. Amount of Rescue Medication Taken

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified week were summarized.

    Measured: Week 2, 4, 8, 12, 16, 24

  26. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 32 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included both serious and all non-serious adverse events.

    Measured: Baseline up to Week 32

  27. Change From Baseline in Neuropathy Impairment Score (NIS) at Week 2, 4, 6, 8, 12, 16 and 24

    The NIS is a standardized instrument used to evaluate participant for signs of peripheral neuropathy. Neurologic examination assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense and pin prick) of index fingers and great toes in order to complete the NIS. The NIS is the sum of scores of over all 37 items (24 scored 0-4; 13 scored 0-2), made separately for left and right sides, giving a possible overall score range of 0 (no impairment) to 122 (severe impairment). NIS Total score range (total of both left and right sides) was 0 (no impairment) to 244 (severe impairment), where higher scores indicated increased impairment.

    Measured: Baseline, Week 2, 4, 6, 8, 12, 16, 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2008 (estimated)
  2. Study start17 Nov 2008
  3. Primary completion15 Mar 2010
  4. Study completion13 Aug 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
627 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00744471
Sponsor's protocol ID
A4091014
Other IDs
P3 OA HIP
Status last verified
Feb 2021
First submitted
29 Aug 2008
Last updated
26 Feb 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.

    PubMed 37460782
  • Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

    PubMed 30936738
  • Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

    PubMed 26554876
  • Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950.

    PubMed 23553790

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing tanezumab in people with Arthritis and Osteoarthritis, run by Pfizer at 99 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 99 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward (BOCF) (time frame: Baseline (Day 1), Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00744471, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in